Article Text

Download PDFPDF
Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease
  1. Talal Alzahrani1,
  2. Abdulelah Nuqali1,
  3. Nejat Naser1 and
  4. Amar R Jariwala2
  1. 1 Department of Medicine, The George Washington University, Washington, District of Columbia, USA
  2. 2 Department of Pathology, The George Washington University, Washington, District of Columbia, USA
  1. Correspondence to Dr Abdulelah Nuqali, abdulelah.n{at}


We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.

  • haematology (drugs and medicines)
  • crohn’s disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TA, AN, NN and ARJ contributed to the writing of the manuscript. ARJ also edited the pathology slides and wrote the description of the figures.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.